Sintokamide A is a novel antagonist of androgen receptor that uniquely binds activation function-1 in its amino-terminal domain

Journal of Biological Chemistry

Volumn 291, Issue 42, 2016, Pages 22231-22243

  Banuelos, Carmen A ^a   Tavakoli, Iran ^a   Tien, Amy H ^a   Caley, Daniel P ^a   Mawji, Nasrin R ^a   Li, Zhenzhen ^a,b   Wang, Jun ^a   Yang, Yu Chi ^a   Imamura, Yusuke ^a   Yan, Luping ^c   Wen, Jian Guo ^d   Andersen, Raymond J ^c   Sadar, Marianne D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b ZHENGZHOU UNIVERSITY   (China)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; BINS; CHEMICAL ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; LIGANDS; UROLOGY;

ACTIVATION FUNCTIONS; AMINO-TERMINAL DOMAIN; CONSTITUTIVELY ACTIVES; LIGAND BINDING DOMAIN; MECHANISMS OF RESISTANCES; PROSTATE CANCER CELLS; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTIONAL ACTIVITY;

DISEASES;

ACTIVATION FUNCTION 1 INHIBITOR; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANTIANDROGEN; BICALUTAMIDE; DIMETHYL SULFOXIDE; ENZALUTAMIDE; EPI 001; EPI 002; EPI 014; EPI 053; EPI 506; LPY 19; LPY 30; LPY 31; METRIBOLONE; NATURAL PRODUCT; PROSTATE SPECIFIC ANTIGEN; SINTOKAMIDE A; STAT3 PROTEIN; UNCLASSIFIED DRUG; 2 PYRROLIDONE DERIVATIVE; STAT3 PROTEIN, HUMAN; TUMOR PROTEIN;

ACTIVATION FUNCTION 1 REGION; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DRUG BINDING SITE; DRUG STRUCTURE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; TRANSACTIVATION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; NONOBESE DIABETIC MOUSE; PROSTATIC NEOPLASMS; SCID MOUSE; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEIN DOMAINS; PYRROLIDINONES; RECEPTORS, ANDROGEN; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION;

EID: 84991684378     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M116.734475     Document Type: Article

References (37)

1. Jenster, G., van der Korput, H. A., van Vroonhoven, C., van der Kwast, T. H., Trapman, J., and Brinkmann, A. O. (1991) Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol. Endocrinol. 5, 1396-1404
2. Simental, J. A., Sar, M., Lane, M. V., French, F. S., and Wilson, E. M. (1991) Transcriptional activation and nuclear targeting signals of the human androgen receptor. J. Biol. Chem. 266, 510-518
3. Jenster, G., van der Korput, H. A., Trapman, J., and Brinkmann, A. O. (1995) Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J. Biol. Chem. 270, 7341-7346
4. Andersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J. K., Watt, K., Tam, T., Yang, Y. C., Bañuelos, C. A., Williams, D. E., McEwan, I. J., Wang, Y., and Sadar, M. D. (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17, 535-546
5. Myung, J. K., Banuelos, C. A., Fernandez, J. G., Mawji, N. R., Wang, J., Tien, A. H., Yang, Y. C., Tavakoli, I., Haile, S., Watt, K., McEwan, I. J., Plymate, S., Andersen, R. J., and Sadar, M. D. (2013) An androgen receptor N-terminal domain antagonist for treating prostate cancer. J. Clin. Investig. 123, 2948-2960
6. Imamura, Y., Tien, A. H., Pan, J., Leung, J. K., Banuelos, C. A., Jian, K., Wang, J., Mawji, N. R., Fernandez, J. G., Lin, K.-S., Andersen, R. J., and Sadar, M. D. (2016) An imaging agent to detect androgen receptor and its active splice variants in prostate cancer. JCI Insight 1, e87850
7. Sadar, M. D., Williams, D. E., Mawji, N. R., Patrick, B. O., Wikanta, T., Chasanah, E., Irianto, H. E., Soest, R. V., and Andersen, R. J. (2008) Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. Org Lett. 10, 4947-4950
8. Sadar, M. D. (1999) Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J. Biol. Chem. 274, 7777-7783
9. Zhang, X., Morrissey, C., Sun, S., Ketchandji, M., Nelson, P. S., True, L. D., Vakar-Lopez, F., Vessella, R. L., and Plymate, S. R. (2011) Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 6, e27970
10. Poujol, N., Wurtz, J. M., Tahiri, B., Lumbroso, S., Nicolas, J. C., Moras, D., and Sultan, C. (2000) Specific recognition of androgens by their nuclear receptor. A structure-function study. J. Biol. Chem. 275, 24022-24031
11. Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., Wasielewska, T., Welsbie, D., Chen, C. D., Higano, C. S., Beer, T. M., et al. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787-790
12. Masiello, D., Cheng, S., Bubley, G. J., Lu, M. L., and Balk, S. P. (2002) Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J. Biol. Chem. 277, 26321-26326
13. Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E. D., Cai, L., Aparicio, A., Dorow, S., Arora, V., Shao, G., Qian, J., et al. (2012) ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 72, 1494-1503
14. Ueda, T., Bruchovsky, N., and Sadar, M. D. (2002) Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem. 277, 7076-7085
15. Sun, S., Sprenger, C. C., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., Nelson, P. S., and Plymate, S. R. (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Investig. 120, 2715-2730
16. Hörnberg, E., Ylitalo, E. B., Crnalic, S., Antti, H., Stattin, P., Widmark, A., Bergh, A., and Wikström, P. (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castrationresistance and short survival. PLoS One 6, e19059
17. Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., Lotan, T. L., Zheng, Q., De Marzo, A. M., Isaacs, J. T., Isaacs, W. B., et al. (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028-1038
18. Scher, H. I., Lu, D., Schreiber, N. A., Louw, J., Graf, R. P., Vargas, H. A., Johnson, A., Jendrisak, A., Bambury, R., Danila, D., McLaughlin, B., Wahl, J., Greene, S. B., Heller, G., Marrinucci, D., et al. (2016) Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 10.1001/jamaoncol.2016.1828
19. Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., Bova, G. S., and Luo, J. (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16-22
20. Hu, R., Lu, C., Mostaghel, E. A., Yegnasubramanian, S., Gurel, M., Tannahill, C., Edwards, J., Isaacs, W. B., Nelson, P. S., Bluemn, E., Plymate, S. R., and Luo, J. (2012) Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 72, 3457-3462
21. Kato, M., Banuelos, C. A., Imamura, Y., Leung, J. K., Caley, D. P., Wang, J., Mawji, N. R., and Sadar, M. D. (2016) Cotargeting androgen receptor splice variants and mTOR signaling pathway for the treatment of castration-resistant prostate cancer. Clin. Cancer Res. 22, 2744-2754
22. Yang, Y. C., Banuelos, C. A., Mawji, N. R., Wang, J., Kato, M., Haile, S., McEwan, I. J., Plymate, S., and Sadar, M. D. (2016) Targeting androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer. Clin. Cancer Res. 22, 4466-4477
23. Rathkopf, D. E., Smith, M. R., de Bono, J. S., Logothetis, C. J., Shore, N. D., de Souza, P., Fizazi, K., Mulders, P. F., Mainwaring, P., Hainsworth, J. D., Beer, T. M., North, S., Fradet, Y., Van Poppel, H., Carles, J., et al. (2014) Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur. Urol. 66, 815-825
24. Scher, H. I., Fizazi, K., Saad, F., Taplin, M. E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., Armstrong, A. J., Flaig, T. W., Fléchon, A., Mainwaring, P., Fleming, M., et al. (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197
25. Payne, H., Bahl, A., Mason, M., Troup, J., and De Bono, J. (2012) Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU Int. 110, 658-667
26. Malik, Z., Payne, H., Ansari, J., Chowdhury, S., Butt, M., Birtle, A., Sundar, S., Eswar, C. V., Hughes, S., and Bahl, A. (2013) Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancer. Adv. Ther. 30, 1041-1066
27. Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C., Albiges, L., Attard, G., Fizazi, K., De Bono, J. S., and Massard, C. (2013) Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann. Oncol. 24, 1807-1812
28. Sadar, M. D. (2011) Small molecule inhibitors targeting the "Achilles' heel" of androgen receptor activity. Cancer Res. 71, 1208-1213
29. Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., Kung, H. J., Brodie, A. M., Edwards, J., and Qiu, Y. (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69, 2305-2313
30. Mostaghel, E. A., Marck, B. T., Plymate, S. R., Vessella, R. L., Balk, S., Matsumoto, A. M., Nelson, P. S., and Montgomery, R. B. (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin. Cancer Res. 17, 5913-5925
31. Korpal, M., Korn, J. M., Gao, X., Rakiec, D. P., Ruddy, D. A., Doshi, S., Yuan, J., Kovats, S. G., Kim, S., Cooke, V. G., Monahan, J. E., Stegmeier, F., Roberts, T. M., Sellers, W. R., Zhou, W., and Zhu, P. (2013) An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 3, 1030-1043
32. Cao, B., Qi, Y., Zhang, G., Xu, D., Zhan, Y., Alvarez, X., Guo, Z., Fu, X., Plymate, S. R., Sartor, O., Zhang, H., and Dong, Y. (2014) Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 5, 1646-1656
33. Sadar, M. D., Hussain, M., and Bruchovsky, N. (1999) Prostate cancer: molecular biology of early progression to androgen independence. Endocr. Relat. Cancer 6, 487-502
34. 2-terminal interaction with the ligand binding domain of the androgen receptor. J. Biol. Chem. 275, 22986-22994
35. Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., Escara-Wilke, J., Wilder-Romans, K., Dhanireddy, S., Engelke, C., Iyer, M. K., Jing, X., Wu, Y. M., Cao, X., Qin, Z. S., et al. (2014) Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278-282
36. De Mol, E., Fenwick, R. B., Phang, C. T., Buzon, V., Szulc, E., de la Fuente, A., Escobedo, A., Garcia, J., Bertoncini, C. W., Estebanez-Perpina, E., McEwan, I. J., Riera, A., and Salvatella, X. (2016) EPI-001, a compound active against castration-resistant prostate cancer, targets transactivation unit 5 of the androgen receptor. ACS Chem. Biol. 10.1021/acschembio.6b00182
37. Hammoudeh, D. I., Follis, A. V., Prochownik, E. V., and Metallo, S. J. (2009) Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J. Am. Chem. Soc. 131, 7390-7401